Independent Risk Factors for Opioid Refills at 31-60 and 61-90 Days After

Spine Surgery: A Retrospective Cohort Study

Lingyi Zhang, MD[1]*, Fang Ye, MD, PhD[1,2]*, Praveen V. Mummaneni, MD, MBA[3], Akash

Shanmugam[4], Andrew Bishara, MD[1], Sigurd H. Berven, MD[5], Christopher R. Abrecht, MD[1],

and Zhonghui Guan, MD[1]

[1]Department of Anesthesia and Perioperative Care, University of California, San Francisco, San

Francisco, CA, United States of America

[2]Anesthesiology Department, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou,

P.R. China

[3]Department of Neurological Surgery, University of California, San Francisco, San Francisco,

CA, United States of America

[4]University of California San Francisco School of Medicine, San Francisco, CA, United States of

America

[5]Department of Orthopaedic Surgery, University of California, San Francisco, San Francisco,

CA, United States of America

*These authors contributed equally.

Corresponding Author

Zhonghui Guan, MD

Department of Anesthesia and Perioperative Care

University of California San Francisco

520 Illinois St

San Francisco, CA 94158

Tel: 415-885-7246

Fax: 415-885-7575

zhonghui.guan@ucsf.edu

Running head: Risk Factors for Opioid Refills

Reprints will not be available from the authors.

Funding: The research is not funded.

Data Availability Statement: The declassified data is available upon request for the purpose of

research only.

Key Words: Opioid refill, spine surgery, risk factor

Mini-Abstract:

Among the independent risk factors identified, opioid refill at 31-60 days after discharge from

spine surgery emerged as the strongest predictor of refill at 61-90 days, with a negative

predictive value of 94.3% and a positive predictive value of 41.5%, suggesting its potential as a

screening marker for high-risk patients.

ABSTRACT

Objective: To identify independent factors associated with opioid refills at 31-60 days and 61-90

days after discharge from spine surgery and to propose a screening marker for high-risk patients.

Background: Although the 2-3 months following surgery are critical for the transition from

short-term to persistent postsurgical opioid use, little is known about opioid refills during this

period.

Methods: This retrospective cohort study included 11,087 adult opioid-naïve and non-opioid-

naïve patients who underwent spine surgery and were discharged between January 2017 and

December 2023. Data were analyzed using multiple logistic and linear regressions and Fisher's

exact test.

Results: Of the patients, 25.4% and 14.8% received opioid refills at 31-60 days and 61-90 days

post-discharge, respectively. Among the independent risk factors, an opioid refill at 31-60 days

was the strongest predictor of a refill at 61-90 days (aOR 6.71, 95% CI 5.90-7.65), regardless of

preoperative opioid use, cervical or lumbar procedures, or surgical service. In fact, refill rates at

61-90 days were linearly correlated with those at 31-60 days ($p < 0.0001$, slope = 0.73). A refill

at 31-60 days predicted a refill at 61-90 days with a negative predictive value (NPV) of 94.3%

and a positive predictive value of 41.5%, with consistently high NPVs across subgroups defined

by preoperative opioid use, surgical procedure, or surgeon. Moreover, a refill at 1-30 days was

associated with increased risks of refills at both 61-90 days (aOR 3.16, 95%CI 2.76-3.62) and

31-60 days (aOR 4.04, 95% CI 3.66-4.46) after discharge. Preoperative use of opioids, cannabis,

and benzodiazepine, as well as the first postoperative pain score recorded on the hospital floor

and a diagnosis of depression, were associated with increased odds of refills at both 31-60 and

61-90 days. In contrast, surgical procedures were largely not associated with refills at either time

point.

Conclusion: Each opioid refill prescription should be carefully managed after spine surgery to

prevent subsequent refills. A refill at 31-60 days after discharge may serve as a simple and

effective screening marker for identifying high-risk patients who could benefit from multimodal

pain management through a transitional pain service (TPS) to mitigate further opioid use.

INTRODUCTION

Persistent opioid use after surgery is a major medical concern among postsurgical patients and contributes to the current opioid crisis[1-4]. Some postsurgical patients continue to use opioids 12 months after their surgical procedures[5-11], requiring considerably more healthcare services[12]. Additionally, patients prescribed postsurgical opioids may misuse them or divert them to others[13], with the risk of such behaviors increasing with each opioid refill and every additional week of opioid use[14, 15].

Approximately 900,000 American adults undergo spine surgery annually[16]. Following cervical spine surgery, 6.3% of opioid-naive patients and 45.3% of non-opioid-naïve patients continued using opioids 12 months post-surgery[5]. After lumbar spine surgery, 8.6% of opioid-naive patients and 42.4% of non-opioid-naïve patients continued using opioids at 12 months[6]. By the third month after spine surgery, opioid use rates decreased substantially compared to the first and second months but were similar to those observed at 12 months post-surgery[5, 6].

While opioid use within the first month after surgery is considered immediate short-term opioid use[17], opioid use beyond three months after surgery is classified as persistent opioid use[18, 19]. Thus, the two-to-three-month period after surgery represents a critical transitional phase from short-term to persistent opioid use. Although previous studies have examined risk factors associated with acute opioid use within the first postsurgical month[17] and persistent opioid use beyond three months[20-26], little is known about opioid use during the transitional two-to-three-month postsurgical period for any type of surgical procedure, including spine surgery.

95 This study included 11,087 adult opioid-naïve and non-opioid-naïve patients who underwent

96 spine surgery, a procedure associated with high rates of persistent post-surgical opioid use[5, 6].

97 The study aimed to identify independent risk factors associated with opioid refills at 31-60 days

98 and 61-90 days after discharge and to develop a simple screening marker to detect high-risk

99 patients likely to require further opioid refills following spine surgery.

METHODS

Study Design and Data Source

This retrospective observational cohort study was approved by the University of California San Francisco (UCSF) Institutional Review Board, which waived the requirement for patient consent to access electronic health record data.

Study Cohort

The cohort included 11,087 adult opioid-naïve and non-opioid-naïve patients who underwent spine surgery performed by orthopedic spine and neuro-spine services at the UCSF Medical Center. Patients had postsurgical hospital stays of at least 24 hours and were discharged between January 2017 and December 2023, a period following the release of the 2016 Centers for Disease Control and Prevention (CDC) guidelines for opioid prescriptions[27].

Outcome and Variables

The primary outcome was prolonged opioid refills prescribed at 31-60 and 61-90 days after hospital discharge. The study did not extend beyond 90 days, as many patients obtained opioid refills from their primary care physicians outside of the UCSF system after three months post-surgery, resulting in incomplete refill records beyond this period. Variables include preoperative opioid (within 6 months before surgery), cannabis, and benzodiazepine usage, first postsurgical pain level on hospital floor, last pain level before discharge, intra-operative oral morphine equivalents (OME), inpatient first 24-hour OME after surgery, inpatient last 24-hour OME before discharge, total OME of prescribed opioids at discharge, daily dose mismatched discharge

opioid prescription, postsurgical usage of non-opioid analgesics (acetaminophen, non-steroidal

anti-inflammatory drugs [NSAIDs], and gabapentinoids), type of the procedures (elective

procedure, laminectomy, tumor resection, spine fusion, cervical procedures, lumbar procedures),

surgical procedures (anterior cervical discectomy and fusion, anterior lumbar spine fusion 2-4

segments, cervical laminoplasty, endoscopic posterior spine fusion 1-2 segments, lateral lumbar

interbody fusion, laminectomy for spinal cord tumor resection, lumbar decompression, posterior

cervical spine fusion 4-7 segments, posterior lumbar spine fusion 1-3 segments, posterior lumbar

spine fusion 4-6 segments, posterior lumbar fusion 7-12 segments, posterior spine fusion ≥13

segments, and posterior spine fusion with resection of spine tumor), neuro-spine vs ortho-spine

service, procedure time in the operating room, return to operating room before discharge,

postsurgical hospital length of stay (LOS), discharge disposition, psychiatric comorbidities

(depression and anxiety), body mass index (BMI), age, sex, race, and ethnicity.

All opioid doses were converted to OME[28]. Similar to previous studies[29-32], opioid daily dose

over-prescription was defined as a maximum prescribed daily dose exceeding the patient's

inpatient daily opioid consumption by at least 7.5 OME, while under-prescription was defined as

a maximum prescribed daily dose of at least 7.5 OME below the patient's inpatient daily opioid

consumption. 7.5 MME was set as the threshold because it corresponds to the dose of a 5 mg

Oxycodone pill, the opioid medication most commonly prescribed opioid after surgery[33], making

it a clinically practical range for aligning daily doses.

Statistical Analyses

Continuous variables, determined to be abnormally distributed by the D'Agostino and Pearson

tests, were presented as medians with interquartile ranges (IQR). Binary variables were presented

as percentages and analyzed using simple linear regression. Negative and positive predictive

values were assessed using two-sided Fisher's exact test. Multiple logistic regression was

performed using the area under the ROC curve, a classification table, and predicted probability

for each subject as classification and prediction methods, and the results were presented as

adjusted odds ratios (aOR) and 95% confidence intervals (CI). All analyses were conducted

using GraphPad Prism 10.3.1, with the statistical significance set at an α value of 0.05.

RESULTS

Demographic Data

As shown in Table 1, among the cohort of 11,087 patients with a median age of 64 years (IQR

54-72), 5,744 (51.8%) self-identified as female, 8,075 (72.8%) as white, 883 (8.0%) as Asian,

632 (5.7%) as black, 163 (1.5%) as Native American or Alaska Natives, 59 (0.5%) as Native

Hawaiian or other Pacific Islanders, and 1,151 (10.4%) as Hispanic or Latino. Additionally,

6,243 (56.3%), 2,115 (19.1%), and 2,071 (18.7%) patients had preoperative use of opioids

(within six months before surgery), cannabis, and benzodiazepines, respectively. During

postoperative hospitalization, 10,386 (93.7%) patients received acetaminophen, 399 (3.6%)

received NSAIDs, and 9974 (90.0%) received gabapentinoids (gabapentin or pregabalin).

A total of 4,151 (37.4%), 2,819 (25.4%), and 1,640 (14.8%) patients received opioid refills at 1-

30, 31-60, and 61-90 days after discharge, respectively. The median first pain level on the ward

floor and last pain level before discharge were 6 (IQR 3-8) and 5 (IQR 3-6) on a 0-10 scale,

respectively. The median OMEs for intra-operative use, the first postsurgical 24 hours on the

hospital floor, the last 24 hours before discharge, and the total dose of discharge opioid

prescriptions were 106.6 (IQR 67.2-204.0), 110.0 (IQR 55.8-199.8), 75.0 (IQR 30.0-132.5) and

450 (IQR 0.0-900.0), respectively. A total of 5,149 (46.6%) patients were overprescribed opioid

daily doses at discharge, while 4,438 (40.0) were under-prescribed.

Previous Opioids Refills are Strongly Associated with Subsequent Opioid Refills

Our multiple logistic regression analyses (Table 2) revealed that, when controlling for other

factors, opioid refill at 31-60 days after discharge was the strongest risk factor associated with an

increased risk of opioid refill at 61-90 days (aOR 6.71, 95% CI 5.90-7.65). Additionally, opioid

refill at 1-30 days was strongly associated with increased risks of refills at both 61-90 days (aOR

3.16, 95% CI 2.76-3.62) and 31-60 days (aOR 4.04, 95% CI 3.66-4.46) after discharge.

Other Postoperative Factors Associated with Prolonged Opioid Refills at 31-60 Days and 61-90

Days After Discharge

Multiple logistic regression analyses also revealed that when other factors were controlled,

postsurgical acetaminophen (aOR 0.55, 95% CI 0.43-0.72) was associated with reduced risks of

opioid refill at 61-90 days after discharge. Discharge to home or self-care was associated with

reduced risks of refills at 61-90 days (aOR 0.82, 95% CI 0.70-0.96) and 31-61 days (aOR 0.84,

95% CI 0.75-0.95) after discharge, respectively.

Additionally, higher first postsurgical pain levels on the ward floor were associated with

increased risks of opioid refill at 61-90 (aOR 1.05, 95% CI 1.02-1.07) and 31-60 days (aOR 1.03,

95% CI 1.02-1.05), whereas higher last pain levels before discharge were associated with an

increased risk of refill at 31-60 days (aOR 1.07, 95% CI 1.05-1.09). The opioid amounts

administered intraoperatively, in the first 24 hours after surgery, and in the last 24 hours before

discharge were not associated with increased or decreased risks of opioid refills. However, a

higher total dose of discharge opioid prescription was associated with an increased risk of opioid

refill at 31-60 days (aOR 1.00008, 95% CI 1.00004-1.00012), but not at 61-90 days after

discharge. Opioid daily dose under-prescription at discharge was associated with an increased

risk of refill at 61-90 days (aOR 1.33, 95% CI 1.08-1.64), while opioid daily dose over-

prescription was not associated with opioid refills.

Preoperative Factors Associated with Opioid Refills at 31-60 Days and 61-90 Days After Discharge

Preoperative opioid use within 6 months before surgery was associated with increased risks of opioid refills at 61-90 days (aOR 1.68, 95% CI 1.45-1.95) and 31-60 days (aOR 1.86, 95% CI 1.67-2.08) after discharge. Pre-operative use of cannabis (aOR 1.25, 95% CI 1.08-1.45) and benzodiazepine (aOR 1.17, 95% CI 1.01-1.35), as well as depression (aOR 2.03, 95% CI 1.38-2.99), were also associated with an increased risk of refills at 61-90 days after discharge. Similarly, preoperative cannabis (aOR 1.26, 95% CI 1.12-1.42) and benzodiazepine (aOR 1.16, 95% CI 1.03-1.30), and depression (aOR 1.404, 95% CI 1.002-1.962) were associated with increased risks of refills at 31-60 days after discharge. Age, sex, race, ethnicity, anxiety, and BMI were not associated with prolonged opioid refills, except that being black was associated with an increased risk of refill at 61-90 days (aOR 1.47, 95% CI 1.05-2.04).

Association between Surgical Procedures and Opioid Refills at 31-60 Days and 61-90 Days After Discharge

Compared to orthopedic spine surgery, neuro-spine surgery was associated with decreased risks of opioid refills at 61-90 (aOR 0.64, 95% CI 0.55-0.73) and 31-60 days (aOR 0.67, 95% CI 0.60-0.74) when other factors were controlled. Overall, specific spine surgical procedures were generally not associated with increased or decreased risks of opioid refills. However, endoscopic posterior spine fusion of 1-2 segments was associated with a decreased risk of opioid refill at 61-90 days (aOR 0.58, 95% CI 0.36-0.91), while anterior spine fusion of 2-4 segments (aOR 1.30,

95% CI 1.07-1.57) and posterior spine fusion of 7-12 segments (aOR 1.37, 95% CI 1.08-1.74)

were associated with an increased risk of opioid refill at 31-60 days.

Trends in the Rates of Opioid Refill at 31-60 Days and 61-90 Days After Discharge

We analyzed the opioid refill rates at 31-60 and 61-90 days from 2017 to 2023 at six-month

intervals. The refill rate at 31-60 days decreased significantly during this period (p = 0.003, slope

= -0.39) (Figure 1a). When the refill rate at 31-60 days was plotted against that at 61-90 days, a

linear correlation was observed (p < 0.0001, slope = 0.73) (Figure 1b).

Strong Association Between Opioid Refills at 31-60 Days and 61-90 Days in Patients With and

Without Pre-operative Opioids, Following Cervical and Lumbar Spine Surgeries, and by

Neurosurgery and Orthopedic Services

Our multiple logistic regression analyses showed that, with other factors controlled, refill at 31-

60 was strongly associated with refill at 61-90 days in patients with (aOR 6.28, 95% CI 5.40-

7.31) and without (aOR 8.01, 95% CI 6.21-10.38) preoperative opioid use (Figure 2a), following

cervical (aOR 6.06, 95% CI 4.74-7.76) and lumbar (aOR 7.60, 95% CI 6.27-9.24) spine surgeries

(Figure 2b), as well as in patients receiving care from neurosurgery (aOR 6.24, 95% CI 5.23-

7.46) and orthopedic (aOR 7.60, 95% CI 6.25-9.27) services (Figure 2c).

Predicting Opioid Refill at 61-90 Days Based on Refill at 31-60 Days After Discharge

We explored the potential of using opioid refill at 31-60 days as a screening marker to predict

subsequent refill at 61-90 days. This approach yielded a negative predictive value (NPV) of

94.3% (Figure 3a). Specifically, for patients with and without pre-operative opioid use, the NPVs

were 92.0% and 96.7%, respectively. For patients undergoing different spine procedures, the

NPVs exceeded 91% across all procedures (ranging from 91.7% in lateral lumbar interbody

fusion to 98.9% in posterior spine fusion with tumor resection), except for posterior spine fusion

of ≥13 segments, which had an NPV of 87.7%. Among the seven neurosurgeons and six

orthopedic surgeons who performed more than 100 procedures during the study period, the

NPVs ranged from 90.6% to 96.0% (Figure 3a). The positive predictive values (PPVs) for the

prediction were 41.5% for the entire cohort, and 45.0% and 32.2% for patients with and without

pre-operative opioid use, respectively. For patients undergoing different spine procedures, the

PPVs ranged from 23.5% to 50.0%. Among the 13 surgeons, the PPVs ranged from 26.4% to

59.4% (Figure 3b).

Opioid refill at 1-30 days after discharge can also be used to predict refill at 61-90 days

(Supplementary Figure 1) or refill at 31-60 days (Supplementary Figure 2); however, it provides

lower PPVs (for 61-90 days) and NPVs (for 31-60 days).

DISCUSSION

To prevent persistent postsurgical opioid use beyond three months after surgery, it is crucial to

implement interventions for high-risk patients before it fully develops. However, little is known

about opioid use during the transitional period of 2-3 months after surgery. In this study, we

identified independent factors associated with opioid refills prescribed at 31-60 days and 61-90

days after discharge from spine surgery, a procedure with a high incidence of persistent

postsurgical opioid use[5, 6]. Among these factors, opioid refill at 31-60 days was the strongest

factor associated with refill at 61-90 days, and the refill rates refills at 61-90 days and 31-60 days

were linearly correlated. Using opioid refill at 31-60 days to predict refill at 61-90 days yielded

an NPV of 94.3% and a PPV of 41.5%. Notably, the NPVs were consistently high, regardless of

preoperative opioid use, procedure, or surgeon.

In this study, we used opioid refill prescriptions as a proxy for opioid use as they serve as a

gateway for patients to access opioids[34]. We found that the strongest independent predictors of

prolonged opioid refills at 31-60 days and 61-90 days were prior opioid refills. After controlling

for other factors, refill at 31-60 days after discharge was associated with a more than six-fold

increase in the odds of refill at 61-90 days. This strong association persisted regardless of

preoperative opioid use, cervical or lumbar spine surgery, or the care provided by orthopedic or

neurosurgical services. Conversely, refill at 1-30 days was associated with a more than three-fold

increase in the odds of refill at 61-90 days and a four-fold increase in the odds of refill at 31-60

days after discharge. These findings highlight the importance of carefully managing each

postsurgical opioid refill prescription after spine surgery to prevent subsequent refills.

As prevention is widely regarded as the most effective strategy for managing chronic diseases[35],

it is likely to be the best approach for addressing persistent postsurgical opioid use. Thus, the

transitional phase of two–three months post-surgery may represent a crucial window for

implementing interventions to prevent persistent postsurgical opioid use. Given the strong

association and linear correlation between refill rates at 31-60 days and 61-90 days after

discharge, opioid refill at 31-60 days may serve as a screening marker to identify high-risk

patients for refills at 61-90 days. This marker demonstrated an NPV of 94.3% and a PPV of

41.5%. In other words, if a patient does not receive opioid refill at 31-60 days, there is a 94.3%

likelihood that the patient will not need refill at 61-90 days. Conversely, if a patient receives a

refill at 31-60 days, there is a 41.5% chance that the patient will require refill at 61-90 days.

Therefore, it may be advisable to refer a patient who receives a refill at 31-60 days after

discharge to a transitional pain service (TPS)[36, 37] for multimodal management to prevent further

opioid use after spine surgery. Since the opioid refill rate in the third month after spine surgery is

close to that at 12 months[5, 6], TPS management aimed at reducing opioid refill during the third

month could likely reduce opioid use by 12 months after surgery. Notably, with 2,819 spine

surgical patients receiving refills at 31-60 days after discharge during our 7-year study period

(Table 1), there were, on average, fewer than eight patients per week, which is well within the

manageable range of a TPS. Although refill at 1-30 days may also serve as a screening marker

for refills at 31-60 and 61-90 days, it has much lower NPVs and PPVs.

Since many post-operative factors are associated with opioid refills at 31-60 and 61-90 days after

discharge, efforts should be made shortly after spine surgery to prevent them. For example,

postsurgical pain should be adequately managed. For every 1-point increase in pain score (on a

scale of 0-10) during the first 24 hours on the hospital floor, there was a 3% and 5% increase in

the odds of opioid refills at 31-60 and 61-90 days, respectively. Additionally, each 1-point

increase in the last pain score before discharge was associated with a 7% increase in the odds of

refill at 31-60 days. Indeed, postsurgical administration of acetaminophen was associated with a

reduced risk of opioid refill at 61-90 days, suggesting that postsurgical use of acetaminophen

should be encouraged after spine surgery to reduce postsurgical pain and lower the likelihood of

prolonged opioid refills. However, when other factors were controlled, the doses of

intraoperative opioid use or inpatient postsurgical opioid consumption, either during the first 24

hours after surgery or the last 24 hours before discharge, were not associated with increased or

decreased risks of opioid refills.

Although substantial efforts have focused on reducing the total dose of discharge opioid

prescriptions based on procedure-centered guidelines[38-40], our study showed that the total dose of

discharge opioid prescriptions was not associated with an increased or decreased risk of opioid

refills at 61-90 days after discharge. While the total prescribed dose was associated with an

increased risk of refills at 31-60 days, the effect was clinically marginal, with each 1 OME

increase corresponding to only a 0.008% increase in odds, or a 0.8% increase in odds for every

100 OME increase. In contrast, opioid daily dose under-prescription, defined as the maximum

daily dose of discharge opioid prescription being at least 7.5 OME lower than the patient's

inpatient opioid consumption during the last 24 hours before discharge, was associated with a

33% increase in the odds of opioid refills at 61-90 days. As one of the strongest predictors of

chronic postsurgical pain is poorly controlled acute pain[37], when the maximum daily dose of

discharge opioid is lower than the patients' daily opioid requirements in opioid daily dose under-

prescribed patients, acute postsurgical pain may be undertreated after discharge, putting patients

at a higher risk of experiencing long-term pain, which could lead to prolonged opioid use after

spine surgery.

Preoperatively, opioid use within 6 months before surgery was associated with 68% and 86%

increases in the odds of opioid refills at 61-90 days and 31-60 days after discharge, respectively.

Preoperative use of cannabis and benzodiazepine, as well as a history of depression, were also

associated with increased risk of refills during both time periods. However, because

postoperative risk factors contribute more substantially to opioid refills at both 31-60 days and

61-90 days than preoperative factors, managing postoperative factors may be more effective in

controlling opioid refills. Moreover, with many postsurgical factors contributing substantially to

opioid refills, identifying high-risk patients solely based on preoperative factors can be

challenging.

As an observational study, our research had the inherent limitations of unmeasured confounding

variables. For example, while we investigated opioid refills, we could not capture the actual

amount of opioids consumed by the patients. Additionally, although our analyses accounted for

the preoperative use of opioids, cannabis, and benzodiazepines, our dataset did not include the

preoperative use of other substances with abuse potential.

Our results suggest that each postsurgical opioid refill prescription after spine surgery should be

carefully managed to prevent subsequent opioid refills. With the strong association and linear

correlation between refill rates at 31-60 and 61-90 days, opioid refill at 31-60 days could serve as

a simple yet effective screening marker to identify high-risk patients who may benefit from

multimodal pain management to reduce subsequent opioid use after spine surgery.

Acknowledgement

The authors thank Athalia Grazette for the data collection.

Competing interests declaration:

P.V.M. has served as a consultant for DePuy Spine, Globus, and Stryker; has direct stock ownership in Spinicity/ISD; has received royalties from DePuy Spine, Thieme Publishers, and Springer Publishing; and has received support from ISSG, NREF, NIH, and AOSpine for non-study-related clinical or research efforts. The other authors declare that they have no conflicts of interest.

REFERENCES

1. Neuman MD, Bateman BT, Wunsch H. Inappropriate opioid prescription after surgery. *Lancet* 2019; 393(10180):1547-1557.
2. Harbaugh CM, Nalliah RP, Hu HM, et al. Persistent Opioid Use After Wisdom Tooth Extraction. *JAMA* 2018; 320(5):504-506.
3. Barth RJ, Jr., Waljee JF. Classification of Opioid Dependence, Abuse, or Overdose in Opioid-Naive Patients as a "Never Event". *JAMA Surg* 2020; 155(7):543-544.
4. Brown CR, Chen Z, Khurshan F, et al. Development of Persistent Opioid Use After Cardiac Surgery. *JAMA Cardiol* 2020; 5(8):889-896.
5. Pugely AJ, Bedard NA, Kalakoti P, et al. Opioid use following cervical spine surgery: trends and factors associated with long-term use. *Spine J* 2018; 18(11):1974-1981.
6. Kalakoti P, Hendrickson NR, Bedard NA, et al. Opioid Utilization Following Lumbar Arthrodesis: Trends and Factors Associated With Long-term Use. *Spine (Phila Pa 1976)* 2018; 43(17):1208-1216.
7. Bedard NA, Pugely AJ, Westermann RW, et al. Opioid Use After Total Knee Arthroplasty: Trends and Risk Factors for Prolonged Use. *J Arthroplasty* 2017; 32(8):2390-2394.
8. Bedard NA, Pugely AJ, Dowdle SB, et al. Opioid Use Following Total Hip Arthroplasty: Trends and Risk Factors for Prolonged Use. *J Arthroplasty* 2017; 32(12):3675-3679.
9. Westermann RW, Anthony CA, Bedard N, et al. Opioid Consumption After Rotator Cuff Repair. *Arthroscopy* 2017; 33(8):1467-1472.
10. Anthony CA, Westermann RW, Bedard N, et al. Opioid Demand Before and After Anterior Cruciate Ligament Reconstruction. *Am J Sports Med* 2017; 45(13):3098-3103.
11. Bedard NA, DeMik DE, Dowdle SB, et al. Trends and risk factors for prolonged opioid use after unicompartmental knee arthroplasty. *Bone Joint J* 2018; 100-B(1 Supple A):62-67.
12. Gerlach EB, Plantz MA, Swiatek PR, et al. The Drivers of Persistent Opioid Use and Its Impact on Healthcare Utilization After Elective Spine Surgery. *Global Spine J* 2024; 14(2):370-379.
13. Porter ED, Sacks OA, Ramkumar N, et al. Surgery Prescription Opioid Misuse and Diversion in US Adults and Associated Risk Factors. *J Surg Res* 2022; 275:208-217.
14. Agniel D, Brat GA, Marwaha JS, et al. Association of Postsurgical Opioid Refills for Patients With Risk of Opioid Misuse and Chronic Opioid Use Among Family Members. *JAMA Netw Open* 2022; 5(7):e2221316.
15. Brat GA, Agniel D, Beam A, et al. Postsurgical prescriptions for opioid naive patients and association with overdose and misuse: retrospective cohort study. *BMJ* 2018; 360:j5790.
16. Cram P, Landon BE, Matelski J, et al. Utilization and Outcomes for Spine Surgery in the United States and Canada. *Spine (Phila Pa 1976)* 2019; 44(19):1371-1380.
17. Larach DB, Sahara MJ, As-Sanie S, et al. Patient Factors Associated With Opioid Consumption in the Month Following Major Surgery. *Ann Surg* 2021; 273(3):507-515.
18. Sun EC, Rishel CA, Waljee JF, et al. Association Between State Limits on Opioid Prescribing and the Incidence of Persistent Postoperative Opioid Use Among Surgical Patients. *Ann Surg* 2023; 277(4):e759-e765.

19. Fernandez AC, Bohnert A, Gunaseelan V, et al. Identifying Persistent Opioid Use After
Surgery: The Reliability of Pharmacy Dispensation Databases. *Ann Surg* 2023;
278(1):e20-e26.
20. Goyal A, Payne S, Sangaralingham LR, et al. Incidence and risk factors for prolonged
postoperative opioid use following lumbar spine surgery: a cohort study. *J Neurosurg*
Spine 2021:1-9.
21. Soneji N, Clarke HA, Ko DT, et al. Risks of Developing Persistent Opioid Use After
Major Surgery. *JAMA Surg* 2016; 151(11):1083-1084.
22. Brummett CM, Waljee JF, Goesling J, et al. New Persistent Opioid Use After Minor and
Major Surgical Procedures in US Adults. *JAMA Surg* 2017; 152(6):e170504.
23. O'Hara NN, Pollak AN, Welsh CJ, et al. Factors Associated With Persistent Opioid Use
Among Injured Workers' Compensation Claimants. *JAMA Netw Open* 2018;
1(6):e184050.
24. Wang MC, Lozen AM, Laud PW, et al. Factors associated with chronic opioid use after
cervical spine surgery for degenerative conditions. *J Neurosurg Spine* 2019:1-8.
25. Rosenthal BD, Suleiman LI, Kannan A, et al. Risk Factors for Prolonged Postoperative
Opioid Use After Spine Surgery: A Review of Dispensation Trends From a State-run
Prescription Monitoring Program. *J Am Acad Orthop Surg* 2019; 27(1):32-38.
26. Ziino C, Karhade AV, Schoenfeld AJ, et al. Characteristics of postoperative opioid
prescription use following lumbar discectomy. *J Neurosurg Spine* 2021; 35(6):710-714.
27. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic
Pain - United States, 2016. *MMWR Recomm Rep* 2016; 65(1):1-49.
28. McPherson MLM, American Society of Health-System Pharmacists. Demystifying
opioid conversion calculations : a guide for effective dosing. Second edition. ed.
Bethesda, MD: American Society of Health-System Pharmacists, 2019.
29. Campbell LJ, Mummaneni PV, Letchuman V, et al. Mismatched opioid prescription in
patients discharged after neurological surgeries: a retrospective cohort study. *Pain* 2023;
164(11):2615-2621.
30. Kuo J, Langnas E, Zhang L, et al. Opioid Overprescription and Underprescription to
Patients After Otolaryngology-Head and Neck Surgery. *JAMA Otolaryngol Head Neck*
Surg 2023; 149(8):756-758.
31. Guan LS, Langnas E, Bongiovanni T, et al. Discharge Opioid Over- and
Underprescription to Patients after General Surgery: A Retrospective Cohort Study. *J Am*
Coll Surg 2023; 237(2):332-342.
32. Chen VJ, Guan LS, Bokoch MP, et al. Mismatched Postsurgical Opioid Prescription to
Liver Transplant Patients: A Retrospective Cohort Study From a Single High-volume
Transplant Center. *Transplantation* 2024; 108(2):483-490.
33. Michigan OPEN. Opioid Presribing Recommendations. https://michigan-
open.org/prescribing-recommendations/.
34. Waljee JF, Li L, Brummett CM, et al. Iatrogenic Opioid Dependence in the United States:
Are Surgeons the Gatekeepers? *Ann Surg* 2017; 265(4):728-730.
35. Rattay KT, Henry LMG, Killingsworth RE. Preventing Chronic Disease:: The Vision of
Public Health. *Dela J Public Health* 2017; 3(2):52-56.
36. Huang A, Azam A, Segal S, et al. Chronic postsurgical pain and persistent opioid use
following surgery: the need for a transitional pain service. *Pain Manag* 2016; 6(5):435-
43.

37. Hollmann MW, Rathmell JP, Lirk P. Optimal postoperative pain management: redefining
the role for opioids. *Lancet* 2019; 393(10180):1483-1485.
38. Vu JV, Howard RA, Gunaseelan V, et al. Statewide Implementation of Postoperative
Opioid Prescribing Guidelines. *N Engl J Med* 2019; 381(7):680-682.
39. Howard R, Waljee J, Brummett C, et al. Reduction in Opioid Prescribing Through
Evidence-Based Prescribing Guidelines. *JAMA Surg* 2018; 153(3):285-287.
40. Krauss WE, Habermann EB, Goyal A, et al. Impact of Opioid Prescribing Guidelines on
Postoperative Opioid Prescriptions Following Elective Spine Surgery: Results From an
Institutional Quality Improvement Initiative. *Neurosurgery* 2021; 89(3):460-470.
462

FIGURE LEGENDS

Figure 1. Rates of opioid refills at 31-60 days and 61-90 days after discharge from spine surgery.

a. The rate of opioid refill at 31-60 days after discharge significantly decreased from 2017 to 2023.

b. There is a linear relationship between the rates of opioid refills at 31-60 days and 61-90 days after discharge.

Data were analyzed using linear regression.

Figure 2. Strong association between opioid refills at 31-60 days and 61-90 days after discharge from spine surgery.

With other variables controlled, opioid refills at 31-60 days after discharge were strongly and independently associated with opioid refills at 61-90 days among patients with or without pre-operative opioids (**a**), following cervical or lumbar procedures (**b**), and across neurosurgery or orthopedics (**c**).

The other controlled variables are listed in the methods section. Data were analyzed using multiple logistic regression, with $p<0.0001$ for each analysis.

Figure 3. Using opioid refill at 31-60 days after discharge to predict a refill at 61-90 days.

Negative (**a**) and positive (**b**) predictive values are presented for the whole cohort, with or without preoperative opioids, across different spine procedures, and by different surgeons. Data were analyzed using two-sided Fisher's exact test, with $p<0.0001$ for each analysis.

Table 1. Demographic data of 11,087 spine surgical patients

Age (years), median (IQR)	64 (54-72)
Self-identified sex, No. (%)	
Male	5,338 (48.1)
Female	5,744 (51.8)
Self-identified race and ethnicity, No. (%)	
Asian	883 (8.0)
Black	632 (5.7)
Native American or Alaska Natives	163 (1.5)
Native Hawaiian or Other Pacific Islander	59 (0.5)
White	8,075 (72.8)
Hispanic or Latino	1,151 (10.4)
Opioid refill prescription after discharge, No. (%)	
1-30 days	4,151 (37.4)
31-60 days	2,819 (25.4)
61-90 days	1,640 (14.8)
Pre-op medications, No. (%)	
Opioids (up to 6 months before surgery)	6,243 (56.3)
Cannabis	2,115 (19.1)
Benzodiazepine	2,071 (18.7)
Opioid dosage (OME), median (IQR)	
Intra-op	106.6 (67.2-204.0)
Inpatient first 24h	110.0 (55.8-199.8)
Inpatient last 24h	75.0 (30.0-132.5)
Discharge prescription total dose	450.0 (0.0-900.0)
Discharge opioid prescription	
Daily dose over-prescription	5,149 (46.4)
Daily dose matched prescription	1,500 (13.5)
Daily dose under-prescription	4,438 (40.0)
Pain level, median (IQR)	
First postsurgical floor pain level	6 (3-8)
Last pain level before discharge	5 (3-6)
Post-op non-opioid analgesic, No. (%)	
Acetaminophen	10,386 (93.7)
Nonsteroidal anti-inflammatory drug (NSAID)	399 (3.6)
Gabapentinoid	9974 (90.0)
Psychiatric comorbidity, No. (%)	
Depression	194 (1.7)
Anxiety	88 (0.8)
Characteristics of surgery, No. (%)	
Neurosurgery	7,127 (64.3)
Orthopedic surgery	3,960 (35.7)
Cervical procedures	3,498 (31.6)
Lumbar procedures	4,770 (43.02)
Laminectomy	2,683 (24.2)
Tumor resection	415 (3.7)
Spine fusion	7,989 (72.1)
Elective procedures	10,083 (90.9)
Return to operating room before discharge	1,938 (17.5)
Discharge to home or self-care	3,712 (33.5)
Individual procedure, No. (%)	
Anterior cervical discectomy and fusion (ACDF)	1,317 (11.9)
Anterior lumbar spine fusion 2-4 segments	1,005 (9.1)
Cervical laminoplasty	363 (3.3)
Endoscopic posterior spine fusion 1-2 segment	361 (3.3)
Laminectomy for spinal cord tumor resection	205 (1.8)
Lateral Lumbar Interbody Fusion (LLIF)	281 (2.5)
Lumbar decompression	722 (6.5)
Posterior cervical spine fusion 4-7 segments	804 (7.3)
Posterior lumbar spine fusion 1-3 segments	651 (5.9)
Posterior lumbar spine fusion 4-6 segments	369 (3.3)
Posterior spine fusion 7-12 segments	644 (5.8)
Posterior spine fusion ≥13 segments	234 (2.1)
Posterior spine fusion with resection of spine tumor	120 (1.1)
Procedure length (min) , median (IQR)	192 (131-282)
Post-op hospital length of stay (LOS) (days) , median (IQR)	4 (3-7)
BMI, median (IQR)	27.6 (24.1-32.1)

Table 2. Independent risk factors associated with opioid refill prescriptions 61-90 and 31-60 days after discharge from spine surgeries. aOR: adjusted odds ratio; CI: confidence interval.

Variables	Refill 61-90 days after discharge		Refill 31-60 days after discharge	
	aOR	95% CI	aOR	95% CI
Opioid refill 31-60d	6.71	5.90-7.65		
Opioid refill 1-30d	3.16	2.76-3.62	4.04	3.66-4.46
Pre-op opioids (up to 6 months before surgery)	1.68	1.45-1.95	1.86	1.67-2.08
Pre-op cannabis	1.25	1.08-1.45	1.26	1.12-1.42
Pre-op benzodiazepine	1.17	1.01-1.35	1.16	1.03-1.30
1st postsurgical floor pain level (VAS score)	1.05	1.02-1.07	1.03	1.02-1.05
Last pain level before discharge (VAS score)	1.02	0.99-1.05	1.07	1.05-1.09
Intra-op OME	0.99998	0.99988-1.00001	0.99999	0.99997-1.00001
Post-op 1st 24h OME	1.00004	0.99987-1.00020	1.00011	0.99996-1.00030
Post-op last 24 OME before discharge	1.00030	0.99977-1.00081	0.99963	0.99918-1.00006
Discharge prescription total OME	1.00004	1.00000-1.00009	1.00008	1.00004-1.00012
Opioid daily dose under-prescription at discharge	1.33	1.08-1.64	1.12	0.96-1.32
Opioid daily dose over-prescription at discharge	1.12	0.91-1.38	0.89	0.77-1.04
Post-op acetaminophen	0.55	0.43-0.72	0.85	0.69-1.05
Post-op NSAID	0.77	0.54-1.08	0.76	0.58-0.98
Post-op gabapentinoids	0.98	0.78-1.22	0.94	0.79-1.11
Discharge to home or self-care	0.82	0.70-0.96	0.84	0.75-0.95
Neurosurgery (vs orthopedics)	0.64	0.55-0.73	0.67	0.60-0.74
Elective procedure	1.05	0.81-1.36	1.03	0.85-1.24
Laminectomy	0.74	0.50-1.08	0.77	0.56-1.06
Tumor resection	0.53	0.21-1.26	1.59	0.86-2.89
Spine fusion	0.76	0.51-1.12	1.10	0.80-1.52
Cervical procedures	1.08	0.81-1.43	0.96	0.77-1.20
Lumbar procedures	0.97	0.76-1.24	1.06	0.88-1.28
Procedure length (min)	1.0004	0.9999-1.0010	1.0003	0.9999-1.0007
Return to operating room before discharge	1.02	0.85-1.22	1.07	0.93-1.22
Post-op hospital length of stay (days)	1.00	0.99-1.02	1.00	0.99-1.01
Anterior cervical discectomy and fusion (ACDF)	1.05	0.79-1.41	1.00	0.80-1.25
Anterior spine fusion 2-4 segments	1.11	0.87-1.42	1.30	1.07-1.57
Cervical laminoplasty	0.77	0.47-1.23	1.23	0.86-1.75
Endoscopic posterior spine fusion 1-2 segments	0.58	0.36-0.91	0.98	0.72-1.34
Lateral lumbar interbody fusion (LLIF)	1.09	0.75-1.57	1.11	0.82-1.48
Laminectomy for spinal cord tumor resection	1.09	0.41-3.06	0.63	0.33-1.22
Lumbar decompression	0.72	0.48-1.07	0.87	0.64-1.16
Posterior cervical spine fusion 4-7 segments	0.91	0.66-1.26	1.05	0.82-1.34
Posterior lumbar spine fusion 1-3 segments	1.11	0.84-1.48	1.09	0.88-1.37
Posterior lumbar spine fusion 4-6 segments	1.21	0.85-1.70	1.19	0.91-1.56
Posterior spine fusion 7-12 segments	0.84	0.61-1.15	1.37	1.08-1.74
Posterior spine fusion $\geq$ 13 segments	1.37	0.89-2.08	1.32	0.93-1.85
Posterior spine fusion with resection of spine tumor	1.65	0.60-4.72	0.82	0.41-1.64
Age (years)	1.000	0.994-1.005	0.9964	0.9924-1.0004
Female	0.99	0.87-1.13	1.06	0.96-1.17
Depression	2.03	1.38-2.99	1.404	1.002-1.962
Anxiety	1.54	0.83-2.76	0.79	0.47-1.32
BMI	1.008	0.998-1.018	1.002	0.995-1.010
Asian	1.40	0.99-1.97	0.94	0.72-1.22
Black	1.47	1.05-2.04	1.20	0.93-1.56
Native American or Alaska Native	1.42	0.85-2.32	1.07	0.71-1.59
Native Hawaiian or Other Pacific Islander	1.58	0.68-3.41	0.98	0.49-1.88
White	0.97	0.76-1.24	0.91	0.76-1.10
Hispanic or Latino	0.93	0.72-1.19	1.09	0.90-1.32

a

b

Figure 1

a

b

c

Figure 2

Figure 3